BERLIN (MedPage Today) —Three-quarters of patients with moderate-to-severe rheumatoid arthritis responded to treatment with the oral JAK inhibitor baricitinib compared with placebo,a researcher said here.
MedPageToday.com –medical news plus CME for physicians












































